HC Wainwright & Co. analyst Douglas Tsao maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $11 to $15.
Keybanc Maintains Overweight on Globant, Lowers Price Target to $232
Keybanc analyst Thomas Blakey maintains Globant (NYSE:GLOB) with a Overweight and lowers the price target from $291 to $232.